Earned income disappears the moment you stop working. Dividend income keeps arriving every quarter. That distinction drives ...

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD ...

Passive income is the cash flow that arrives whether you are working, sleeping, or watching the market churn. For investors ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the ...

J&J investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease: Chicago, Illinois Thursd ...

JNJ stock faces pressure despite strong earnings and dividend growth. Explore how s&p today trends and sector rotation impact ...

We have recently shared Jim Cramer Made A Big Prediction About OpenAI & Discussed These 20 Stocks. Johnson & Johnson ...

A new fixed-dose co-antibody therapy appears to be effective for managing ulcerative colitis and Crohn disease.

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from ...

Johnson & Johnson is scheduled to announce its earnings on Tuesday, April 15, 2025. Analysts expect earnings of $2.59 per share on revenue of $21.6 billion for the current year, compared to $2.71 per ...